Table 1.
Patient and Treatment Characteristics.
| Variable | Number of patients (%) | Median (range) |
|---|---|---|
| Age | 70 (48-90) | |
| Gender | ||
| Male | 37 (79%) | |
| Female | 10 (21%) | |
| Cause of underlying chronic liver disease | ||
| Alcohol | 22 (47%) | |
| Hepatitis B | 13 (28%) | |
| Hepatitis C | 22 (47%) | |
| Non-alcoholic steatohepatitis | 2 (4%) | |
| Child Pugh score | ||
| A5 | 27 (57%) | |
| A6 | 11 (24%) | |
| B7 | 9 (19%) | |
| ALBI grade | ||
| 1 | 20 (43%) | |
| 2 | 24 (51%) | |
| 3 | 3 (6%) | |
| HCC thrombus | ||
| Absent | 21 (45%) | |
| Present | 26 (55%) | |
| Previous Treatment | ||
| Any | 23 (49%) | |
| None | 24 (51%) | |
| In-field tumor response at 3 months post SBRT | ||
| Stable disease | 21 (45%) | |
| Partial response | 15 (32%) | |
| Complete response | 1 (2%) | |
| Unknown | 10 (21%) | |
| Baseline laboratory values | ||
| Bilirubin, μmol/L | 14 (6-42) | |
| Albumin, g/L | 38 (23-47) | |
| Platelet, × 109/L | 117 (55-366) | |
| Gross tumor volume, mL | 96.8 (1.3-1385.1) | |
| Prescription dose, Gy | 33 (30-54) | |
| Liver mean dose, Gy | 15.3 (4.3-18.2) | |
| D800cc, Gy | 7.4 (0-25.3) | |
| Veff, % | 39 (9-60) | |
| Liver volume, mL | 1231.4 (750-3080.7) |